by Xia & He Publishing Inc. We summarize the clinical experience and evidence for conversion therapy in patients with “potentially resectable” HCC from four perspectives. Credit: Ming Zhao, Ning Lyu, Qi-Feng Chen, Song Chen Hepatocellular carcinoma (HCC) presents significant challenges due to its high incidence and mortality rates, particularly in China where most patients are diagnosed at intermediate or advanced stages. This limits the applicability of curative surgical treatments to only 30% of cases, resulting in a five-year survival rate of 14.2%. Recent advancements in locoregional and systemic therapies have Read More